Background Multidrug resistance is a major reason for poor treatment results in advanced
hepatoblastoma (HB). Several alternative treatment options are currently under investigation …

Angiogenesis and signaling through the RAF/mitogen-activated protein/extracellular signal-
regulated kinase (ERK) kinase (MEK)/ERK cascade have been reported to play important …

Background: Sorafenib has recently been shown to reduce tumour growth in
hepatoblastoma (HB) xenografts. The effect of a combined administration with cytostatic …

Purpose: The purpose of this study was to determine the impact of sorafenib on
PI3K/AKT/mTOR signaling pathway and to further define its mechanism for treating …

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Vascular
endothelial growth factor, platelet derived growth factor and the Raf/mitogen‐activated …

Objective: The goal of this study is to investigate the effects of sorafenib on tumor growth,
recurrence and metastasis after curative resection of liver cancer. Research methods …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) is a particularly vascularized solid
tumor where the Raf/MEK/ERK pathway is activated; suggesting that inhibition of this …

Background: Currently, sorafenib is the only systemic chemotherapy drug for advanced
stage Hepatocellular carcinoma (HCC). However, emerging data from some clinical HCC …

Background: Sorafenib is an oral multi-kinase inhibitor that inhibits hepatocellular carcinoma
(HCC) via the Ras/Raf/MAPK pathway. However, sorafenib loses effectiveness because …